| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 8.29 | 23.5% | 8.8% |
| Total Income | 8.29 | 23.5% | 8.8% |
| Expenditure | 10.26 | 11.4% | 4.8% |
| PBT | -1.94 | 165.8% | 26.8% |
| Net Profit | -1.94 | 162.2% | 26.0% |
| OPM | -23.70% | 16.80pp | 5.05pp |
| NPM | -23.40% | 16.57pp | 6.41pp |
| EPS | -0.13 | 160.0% | 18.2% |
Cumberland Pharmaceuticals Reports 12% Year-to-Date Revenue Growth
04 May 2026 · 4 May, 8:16 am
Summary
Cumberland Pharmaceuticals reported net revenues of $8.3 million for the third quarter of 2025. Year-to-date revenues reached $30.8 million, a 12% increase compared to the same period in 2024. The company's net loss for the quarter was approximately $1.9 million, with an adjusted loss of $0.8 million. Recent company developments include the addition of Talicia® to their commercial product portfolio through a collaboration with RedHill Biopharma Ltd.
Key Highlights
- 1
Cumberland Pharmaceuticals' product portfolio delivered net revenues of $8.3 million during the third quarter of 2025.
- 2
Year-to-date revenues for the first nine months of 2025 totaled $30.8 million, representing an increase of 12% over the first nine months of 2024.
- 3
The company ended the quarter with approximately $66 million in total assets and $26 million of shareholders’ equity.
- 4
Third quarter net loss was approximately $1.9 million, while the adjusted loss was $0.8 million, or $0.06 per share.
- 5
Adjusted earnings for the first nine months of 2025 was $1.9 million, or $0.13 per diluted share.
- 6
Cumberland recently announced arrangements with RedHill Biopharma Ltd. to jointly commercialize Talicia®, adding it to its commercial product portfolio.
Management Comments
A.J. Kazimi
We are very pleased to add an established, FDA approved brand to our commercial portfolio. We are also encouraged by the continued progress with our development programs designed to address a series of unmet medical needs in orphan patient populations. As we move into the final quarter of 2025, we remain focused on our mission of working together to provide unique products that improve the quality of patient care.”
Informational and educational content only. Not investment advice.